.INVESTIGATION HIGHLIGHT.06 August 2024.
A large randomized controlled trial with cisgender ladies highlights the problems of adherence to a day-to-day oral preexposure treatment program and displays that twice-yearly treatment of lenacapavir may keep helpful HIV avoidance levels over 6 months.